Jan 25 (Reuters) -
* GENERON SUCCESSFULLY CONCLUDES FIRST PHASE III CLINICAL TRIAL OF F-627 FOR CHEMOTHERAPY-INDUCED NEUTROPENIA
* GENERON CORP- PATIENTS TREATED WITH F-627 DEMONSTRATED SIGNIFICANTLY REDUCED DURATION OF SEVERE NEUTROPENIA COMPARED TO PATENTS IN PLACEBO GROUP â€‹ Source text for Eikon:
 